
Apollo Endosurgery APEN
Annual report 2022
added 03-30-2023
Apollo Endosurgery Book Value 2011-2025 | APEN
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Apollo Endosurgery
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 32.6 M | 61.2 M | 6.75 M | 2.12 M | 28.8 M | 49.9 M | 42.4 M | 10.5 M | 15.8 M | 9.97 M | 14.9 M | 629 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 61.2 M | 629 K | 23 M |
Quarterly Book Value Apollo Endosurgery
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 42.3 M | - | 55 M | 61.2 M | -92 K | 2.71 M | 2.69 M | 6.75 M | 6.75 M | 6.75 M | 6.75 M | 2.12 M | 2.12 M | 2.12 M | 2.12 M | 28.8 M | 28.8 M | 28.8 M | 28.8 M | 49.9 M | 49.9 M | 49.9 M | 49.9 M | 42.4 M | 42.4 M | 42.4 M | 42.4 M | 11.2 M | 10.5 M | 10.5 M | 10.5 M | 15.8 M | 15.8 M | 15.8 M | 15.8 M | 9.97 M | 9.97 M | 9.97 M | 9.97 M | 14.9 M | 14.9 M | 14.9 M | 14.9 M | 629 K | 629 K | 629 K | 629 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 61.2 M | -92 K | 19.4 M |
Book Value of other stocks in the Medical devices industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
GenMark Diagnostics, Inc.
GNMK
|
196 M | - | - | $ 1.77 B | ||
|
Abiomed
ABMD
|
1.33 B | - | - | $ 17.2 B | ||
|
Acutus Medical
AFIB
|
-879 K | - | -26.83 % | $ 2.62 M | ||
|
Lianluo Smart Limited
LLIT
|
272 M | - | 24.59 % | $ 44.8 M | ||
|
Apyx Medical Corporation
APYX
|
26.9 M | $ 3.83 | -0.91 % | $ 133 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
25.5 M | - | -5.86 % | $ 30.6 M | ||
|
Bio-Rad Laboratories
BIO
|
6.57 B | $ 306.74 | -0.45 % | $ 8.65 B | ||
|
BioSig Technologies
BSGM
|
-1.42 M | - | 37.08 % | $ 85.7 M | ||
|
InMode Ltd.
INMD
|
704 M | $ 14.35 | -1.1 % | $ 1.14 B | ||
|
IRIDEX Corporation
IRIX
|
9.52 M | $ 0.99 | 7.52 % | $ 16 M | ||
|
Bruker Corporation
BRKR
|
1.82 B | $ 45.67 | 1.2 % | $ 6.8 K | ||
|
Allied Healthcare Products
AHPI
|
19.7 M | - | 3.58 % | $ 2.21 M | ||
|
Abbott Laboratories
ABT
|
81.4 B | $ 128.62 | 2.52 % | $ 224 B | ||
|
Boston Scientific Corporation
BSX
|
39.4 B | $ 91.86 | -0.78 % | $ 135 B | ||
|
Conformis
CFMS
|
54.2 M | - | - | $ 16.4 M | ||
|
LivaNova PLC
LIVN
|
1.32 B | $ 63.33 | 0.92 % | $ 3.44 B | ||
|
CryoLife, Inc.
CRY
|
58.1 M | - | -4.14 % | $ 702 M | ||
|
EDAP TMS S.A.
EDAP
|
40.9 M | $ 3.19 | 10.76 % | $ 119 M | ||
|
LENSAR
LNSR
|
18.6 M | $ 11.5 | -0.09 % | $ 132 M | ||
|
Cardiovascular Systems
CSII
|
249 M | - | 0.15 % | $ 844 M | ||
|
CHF Solutions, Inc.
CHFS
|
6.23 M | - | 1.15 % | $ 34.5 M | ||
|
Cutera
CUTR
|
-172 M | - | -10.19 % | $ 1.99 M | ||
|
Soliton, Inc.
SOLY
|
243 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
2.61 B | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
229 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
30.4 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
52.2 M | - | - | $ 111 M | ||
|
Eargo
EAR
|
101 M | - | - | $ 10.2 M | ||
|
PAVmed
PAVM
|
-24 M | $ 0.31 | -4.88 % | $ 2.24 M | ||
|
Dynatronics Corporation
DYNT
|
3.26 M | - | 14.99 % | $ 929 K | ||
|
Intersect ENT, Inc.
XENT
|
550 M | - | - | $ 955 M | ||
|
Cognyte Software Ltd.
CGNT
|
217 M | $ 9.6 | -2.64 % | $ 689 M | ||
|
Profound Medical Corp.
PROF
|
31.2 M | $ 7.74 | 5.53 % | $ 180 M | ||
|
Quanterix Corporation
QTRX
|
347 M | $ 7.5 | -0.86 % | $ 282 M | ||
|
IRadimed Corporation
IRMD
|
86.8 M | $ 97.18 | 0.99 % | $ 1.23 B | ||
|
Second Sight Medical Products
EYES
|
17.6 M | - | -0.97 % | $ 54.4 M | ||
|
Align Technology
ALGN
|
3.85 B | $ 163.64 | -1.08 % | $ 12.3 B | ||
|
Accuray Incorporated
ARAY
|
81.2 M | $ 1.05 | -0.94 % | $ 108 M | ||
|
Avinger
AVGR
|
-6.2 M | - | -20.74 % | $ 369 K | ||
|
ClearPoint Neuro
CLPT
|
25.4 M | $ 12.52 | -1.49 % | $ 338 M | ||
|
FONAR Corporation
FONR
|
146 M | $ 14.9 | 1.02 % | $ 97.7 M | ||
|
AxoGen
AXGN
|
104 M | $ 29.72 | -2.2 % | $ 1.32 B | ||
|
Axonics Modulation Technologies
AXNX
|
570 M | - | - | $ 3.31 B | ||
|
GBS
GBS
|
2.81 M | - | -0.57 % | $ 7.12 M | ||
|
CONMED Corporation
CNMD
|
963 M | $ 40.32 | -1.26 % | $ 1.24 B | ||
|
OrthoPediatrics Corp.
KIDS
|
355 M | $ 17.74 | 0.8 % | $ 409 M | ||
|
Globus Medical
GMED
|
4.18 B | $ 86.69 | - | $ 11.8 B | ||
|
Integra LifeSciences Holdings Corporation
IART
|
1.55 B | $ 13.55 | 0.97 % | $ 1.04 B | ||
|
Aziyo Biologics
AZYO
|
-38.6 M | - | 1.37 % | $ 20.5 M |